Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Semaglutide is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Trulicity (dulaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Ozempic (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Semaglutide is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Ozempic (semaglutide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Genetic testing doesn't treat sexual dysfunction — it maps the biological terrain that every treatment decision operates within. The Precision Peptide Genetic Test delivers 6 Sexual Health insights across 14 pathways, 49 peptides, and 150+ genetic insights, giving providers the upstream biological context that bloodwork alone cannot supply — and changing the clinical conversation before any protocol begins.

In the Precision Peptide Genetic Test, the Sexual Health pathway delivers 6 insights across the genes governing central arousal, vascular sexual response, desire, bonding, and circadian sexual timing. Part of 14 pathways, 49 peptides, and 150+ genetic insights, these 6 variants map sexual biology as a connected system — not a checklist of isolated traits.

PDE5 pathway support compounds work differently for different men because the upstream signal they amplify — eNOS-derived nitric oxide — is genetically variable. NOS3 genotype sets the vascular floor. The Precision Peptide Genetic Test maps this and other pathway variables across 14 pathways, 49 peptides, and 150+ genetic insights, explaining the response variability that dosing alone cannot.

Libido has a genetic architecture — DRD2 receptor density, OXTR bonding sensitivity, MTNR1B circadian timing, and MC4R central arousal signaling all shape sexual desire at the neurochemical level. The Precision Peptide Genetic Test maps these variables as part of 14 pathways, 49 peptides, and 150+ genetic insights, explaining the biology of desire that testosterone panels miss.

Erectile function depends on multiple gene-governed systems — nitric oxide production, central arousal signaling, dopamine-driven desire, and cGMP preservation. The Precision Peptide Genetic Test maps the key variants across 14 pathways, 49 peptides, and 150+ genetic insights, identifying the genetic architecture that testosterone panels and vascular tests alone cannot reveal.

Sexual wellness has a genetic architecture — six biological variables that determine how your body produces arousal, routes blood flow, generates desire, and responds to intimacy. The Precision Peptide Genetic Test maps all six as part of 14 pathways, 49 peptides, and 150+ genetic insights, answering the question that hormone panels and bloodwork alone cannot.

Central sexual arousal — the brain-driven signal that initiates the entire sexual response cascade — runs through the melanocortin pathway and its primary receptor, MC4R. The Precision Peptide Genetic Test analyzes melanocortin pathway variants as part of 14 pathways, 49 peptides, and 150+ genetic insights, mapping the CNS architecture of arousal that vascular testing cannot reach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.